Browse
Submit Data
Databases
API
Help

Dataset Information

13 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Guidelines for Prevention and Treatment of Chronic Hepatitis B

ABSTRACT: To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology convened an expert panel in 2019 to update the guidelines for the prevention and treatment of chronic hepatitis B (CHB). The current guidelines cover recent advances in basic, clinical, and preventive studies of CHB infection and consider the actual situation in China. These guidelines are intended to provide support for the prevention, diagnosis, and treatment of CHB.

SUBMITTER: Wang G

PROVIDER: S-EPMC8516840 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.

Project description: Not available

| S-EPMC4033464 | biostudies-literature

Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.

Project description: Not available

| S-EPMC3698425 | biostudies-literature

Autoimmune hepatitis: Appraisal of current treatment guidelines.

Project description: Not available

| S-EPMC6323516 | biostudies-other

Poor adherence to AASLD guidelines for chronic hepatitis B Management and treatment in a large academic medical center.

Project description: Not available

| S-EPMC4624277 | biostudies-literature

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies.

Project description: Not available

| S-EPMC4517705 | biostudies-literature

Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naive Chronic Hepatitis B Patients in Korea.

Project description: Not available

| S-EPMC8042481 | biostudies-literature

Interferon signaling and treatment outcome in chronic hepatitis C

Project description:Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. The current standard therapy for chronic hepatitis C (CHC) consists of a combination of pegylated IFN alpha (pegIFN-alpha) and ribavirin. It achieves a sustained viral clearance in only 50–60% of patients. To learn more about molecular mechanisms underlying treatment failure, we investigated IFN-induced signaling in paired liver biopsies collected from CHC patients before and after administration of pegIFN-alpha. In patients with a rapid virological response to treatment, pegIFN-alpha induced a strong up-regulation of IFN-stimulated genes (ISGs). As shown previously, nonresponders had high expression levels of ISGs before therapy. Analysis of posttreatment biopsies of these patients revealed that pegIFN-alpha did not induce expression of ISGs above the pretreatment levels. In accordance with ISG expression data, phosphorylation, DNA binding, and nuclear localization of STAT1 indicated that the IFN signaling pathway in nonresponsive patients is preactivated and refractory to further stimulation. Some features characteristic of nonresponders were more accentuated in patients infected with HCV genotypes 1 and 4 compared with genotypes 2 and 3, providing a possible explanation for the poor response of the former group to therapy. Taken together with previous findings, our data support the concept that activation of the endogenous IFN system in CHC not only is ineffective in clearing the infection but also may impede the response to therapy, most likely by inducing a refractory state of the IFN signaling pathway. Keywords: Comparison of human patient biopses before and after interferon treatment

2008-04-17 | GSE11190 | GEO

Current progress in the treatment of chronic hepatitis C.

Project description: Not available

| S-EPMC3496882 | biostudies-other

Treatment Options in Patients with Chronic Hepatitis C.

Project description: Not available

| S-EPMC6979812 | biostudies-literature

Therapeutic vaccination for treatment of chronic hepatitis B.

Project description: Not available

| S-EPMC8274149 | biostudies-literature